uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Targeting the epidermal growth factor receptor family in radionuclide therapy of tumors-signal transduction and DNA repair
Ludwig institutet, cancerforskning.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Biomedical Radiation Sciences.
2006 (English)In: Letters in Drug Design & Discovery, ISSN 1570-1808, E-ISSN 1875-628X, Vol. 3, no 6, 357-368 p.Article in journal (Refereed) Published
Abstract [en]

To therapeutically target disseminated tumor cells, while sparing the surrounding tissues, it is necessary to develop agents that interact with structures exposed selectively on the tumor cell surface. Members of the epidermal growth factor receptor family are commonly overexpressed in several tumor types and may serve as targeting structures. In this review we discuss the effects of EGFR and HER2 targeting agents that can deliver radioactive nuclides, i.e. antibodies and affibody molecules, on intracellular signaling. If the targeting agent, in addition to deliver radioactivity to the tumor, can sensitize the tumor for its effects by influencing signal pathways that regulate cell survival and proliferation this will probably be advantageous. We discuss the changes in intracellular signaling that occurs after treatment of cancer cells with the clinically approved monoclonal antibodies cetuximab (anti-EGFR), trastuzumab (anti-HER2) as well as HER2 targeted affibody molecules which are under preclinical development. An important defence mechanism for cells against radiation is to activate DNA repair systems and we also address how DNA repair proteins are regulated in response to radiation or EGFR activation.

Place, publisher, year, edition, pages
2006. Vol. 3, no 6, 357-368 p.
Keyword [en]
EGFR, Radiation, MAPK, AKT, PI3K, Radionuclide, Cancer, Tumor, Therapy
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-104714DOI: 10.2174/157018006777805503OAI: oai:DiVA.org:uu-104714DiVA: diva2:220077
Available from: 2009-05-29 Created: 2009-05-29 Last updated: 2017-12-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Biomedical Radiation Sciences
In the same journal
Letters in Drug Design & Discovery
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 402 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf